REGENXBIO Inc.
RGNXREGENXBIO Inc. (RGNX) is a biotechnology company specializing in the development and commercialization of gene therapy treatments. Founded in 2013, it focuses on leveraging its proprietary NAV Technology platform to create novel therapeutic options for a range of genetic, neurovascular, and retinal diseases. The company's goal is to advance gene therapy science and deliver transformative treatments to patients.
Company News
The choroidal neovascularization therapeutics market is projected to grow significantly between 2025-2034, driven by rising AMD prevalence, technological advancements, and emerging gene therapies targeting vision preservation.
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space. Oppenheimer writes, “We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therap...
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The threat is still emerging, but it could be significant.
